Equillium shares surge 11.43% intraday after regaining Nasdaq compliance with 10 consecutive days above $1, removing delisting risk.

Equillium surged 11.43% intraday, as the company regained compliance with Nasdaq’s minimum stock price requirement after 10 consecutive trading days above $1, eliminating delisting risk. The firm focuses on developing novel therapies for severe autoimmune and inflammatory diseases, currently advancing its clinical-stage drug EQ504.